Regenerative Medical Technology GroupRMTG +3.75% Return-on-Tangible-Equity is 0.00% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 1,197 Biotechnology companies, Regenerative Medical Technology Group ranks worse than 83542.11% on this metric.
The historical rank and industry rank for Regenerative Medical Technology Group's Return-on-Tangible-Equity or its related term are showing as below:
RMTG's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.4 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Regenerative Medical Technology Group (OTCPK:RMTG) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Regenerative Medical Technology Group Return-on-Tangible-Equity Related Terms
Regenerative Medical Technology Group Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group Return-on-Tangible-Equity Chart
RMTG vs PTIX, CERO, EMMA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Regenerative Medical Technology Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenerative Medical Technology Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Regenerative Medical Technology Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Regenerative Medical Technology Group (RMTG) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Regenerative Medical Technology Group and its competitors. According to the industry distribution chart, Regenerative Medical Technology Group ranks #999999 out of 1197 companies in the Biotechnology industry.
Is Regenerative Medical Technology Group's Return-on-Tangible-Equity too high?
Regenerative Medical Technology Group's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Regenerative Medical Technology Group ranks #999999 out of 1197 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regenerative Medical Technology Group's Return-on-Tangible-Equity compare to PTIX and CERO?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #999999 out of 1197 companies for Return-on-Tangible-Equity. This places Regenerative Medical Technology Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Regenerative Medical Technology Group and its competitors. Regenerative Medical Technology Group's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.04 — trading 38.6% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Business Description
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 